BioSpace News Archive

Sight Sciences, Inc., a growth-stage medical device company transforming the two fastest growing segments in ophthalmology and optometry, glaucoma and dry eye disease, today announced the closing of an over $30 million Series E Preferred Stock financing round led by D1 Capital Partners. Proceeds will be used for continued clin

RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) (“the Company” or “RegeneRx”), a clinical-stage drug development company focused on tissue protection, repair and regeneration issued an advisory on its dry eye syndrome Phase 3 clinical trial. To access the advisory, go to the following link: http://www.regenerx.com/2020-03-18-Ma

New high purity resin advances bioprocessing and brings choice and efficiencies to mAbs production workflow processes and protocols

All the benefits of the industry leading BioFlux cell analysis platform, now in a configuration every lab can afford.

Findings highlight uncertainties and differences in response to the crisis based on political affiliation, income and other factors among people age 18 to 64

DXC Technology (NYSE: DXC) today introduced an advanced Patient-Centered Care solution, a customizable and personalized-health offering that gives healthcare providers the technology to meet the high expectations of today’s patients — without sacrificing cost containment and clinician satisfaction.

TOMI Environmental Solutions, Inc.® (“TOMI”) (OTCQB:TOMZ), is a global company specializing in disinfection and decontamination, utilizing its premier Binary Ionization Technology (BIT) platform through its SteraMist products - a hydrogen peroxide-based mist and fog composed of ionized Hydrogen Peroxide (iHP).

A well-known market intelligence company, Infiniti Research, has partnered with several global companies across industries to help meet their strategic objectives and implement seamless route-to-market strategies through turnkey solutions.

Merit Medical Systems, Inc. (NASDAQ: MMSI), a leading manufacturer and marketer of proprietary disposable devices used in interventional, diagnostic and therapeutic procedures, particularly in cardiology, radiology, oncology, critical care and endoscopy, announced today that it experienced an early morning earthquake of 5.7 magnitude.

Opening of New Boston Facility Focused on Cancer Drug Development and Expansion of Expert Oncology Team